Side-by-side · Research reference
ChonlutenvsHCG
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED8/38 cited
BFDA-ApprovedHUMAN-REVIEWED12/52 cited
Chonluten
Khavinson Bioregulator · Bronchial Mucosa
Oral · Sublingual · Per Protocol
HCG
Glycoprotein Hormone · LH Mimetic
IM or SQ · 2–3×/week
01Mechanism of Action
Parameter
Chonluten
HCG
Primary target
Bronchial epithelial cells and respiratory mucosa tissue complexes
LH receptors on testicular Leydig cellsSchröder-Lange 2025
Pathway
Bioregulatory peptide interaction → modulation of proliferative and inflammatory pathways in monocyte/macrophage populationsAvolio 2022
hCG → Leydig cell LH receptor → Intracellular cAMP → Steroidogenesis pathway activation → Testosterone synthesis
Downstream effect
Regulation of proliferative activity and inflammatory mediator production in respiratory-associated immune cellsAvolio 2022
Elevated intratesticular testosterone, restored spermatogenesis, virilization, secondary sex characteristic developmentKonsam 2026Zachariou 2026
Feedback intact?
—
No — exogenous hCG bypasses hypothalamic-pituitary axis; endogenous LH remains suppressed
Origin
Khavinson bioregulator peptide complex derived from bronchial mucosa tissue extract methodology
Heterodimeric glycoprotein (alpha subunit shared with LH/FSH/TSH; beta subunit confers specificity). Available as urinary-derived or recombinant formulations.
Antibody development
—
Rare with recombinant; possible with urinary-derived formulations
02Dosage Protocols
Parameter
Chonluten
HCG
Typical protocol dose
10–20 mg / day
Russian bioregulator tradition dosing; not standardized in Western literature.
—
Frequency
Once or twice daily
—
Route
Oral (capsule) or sublingual
Sublingual claimed for enhanced bioavailability; not validated.
Intramuscular or subcutaneousKonsam 2026
Duration
10–30 days per cycle
Traditional Khavinson protocol; cyclic administration common.
—
Clinical validation
None (PubMed indexed)
—
Hypogonadotropic hypogonadism (monotherapy)
—
2,000 IU IM/SQ 2–3×/weekKonsam 2026Zachariou 2026
Titrate to normalize testosterone (300–1,000 ng/dL) or achieve target AMH ~7.4 ng/mL.
Combined therapy (hCG + FSH)
—
hCG 2,000 IU 2×/wk + rFSH 75 IU 3×/wkKonsam 2026Nariyoshi 2025
Preferred for azoospermia; FSH added after initial hCG phase or from outset.
Triple therapy (experimental)
—
hCG 2,000 IU 2×/wk + rFSH 75 IU 3×/wk + testosterone 100 mg IM q2wkKonsam 2026
May accelerate virilization; reduces hCG requirements (~30% lower cumulative dose vs monotherapy).
Cryptorchidism (pediatric)
—
500–4,000 IU IM 2–3×/week for 3–6 weeks
Duration to sperm appearance
—
12–24 months (median ~18 mo)Huijben 2026Zachariou 2026
Congenital HH may require longer treatment; acquired HH responds faster.
Monitoring
—
Serum testosterone, semen analysis q3–6mo, testicular ultrasound
Thickened seminiferous tubules (>300 μm) on ultrasound predict imminent sperm appearance.Nariyoshi 2025
04Side Effects & Safety
Parameter
Chonluten
HCG
Documented adverse events
No published safety data in PubMed-indexed literature
—
Theoretical risks
Peptide hypersensitivity, GI intolerance (uncharacterized)
—
Drug interactions
Unknown — no pharmacokinetic studies available
—
Pregnancy / lactation
No data — avoid
—
Injection site reaction
—
Pain, erythema (mild, transient)
Gynecomastia
—
Aromatization of elevated testosterone to estradiol; dose-dependent
Testicular discomfort / Edema
—
Rapid testicular growth in hypogonadal males; usually self-limiting
Polycythemia
—
Elevated hematocrit from supraphysiological testosterone; monitor CBC
Mood / Libido changes
—
Variable; usually positive with normalization of testosterone
Acne / Oily skin
—
Androgen-mediated; dose-dependent
Prostate concerns
—
Monitor PSA in older males; hCG restores physiological testosterone (not supraphysiological)
Antibody formation
—
Rare with recombinant; possible with urinary-derived
Absolute Contraindications
Chonluten
- ·Known hypersensitivity to peptide components
HCG
- ·Androgen-dependent malignancy (prostate, breast cancer)
- ·Hypersensitivity to hCG or excipients
- ·Precocious puberty
Relative Contraindications
Chonluten
- ·Pregnancy and lactation (insufficient data)
- ·Active malignancy (theoretical bioregulator concern)
HCG
- ·Untreated obstructive sleep apnea
- ·Severe cardiovascular disease (polycythemia risk)
- ·History of thromboembolism
05Administration Protocol
Parameter
Chonluten
HCG
1. Preparation
Typically supplied as capsules or sublingual tablets. No reconstitution required. Store in cool, dry place away from light.
Add sterile water or bacteriostatic water per manufacturer instructions. Typically 1–2 mL per 5,000–10,000 IU vial. Roll gently — do not shake. Solution should be clear.
2. Oral route
Swallow capsule with water, 20–30 minutes before meals or as directed. Traditional Khavinson protocol emphasizes empty stomach for absorption.
Intramuscular: ventrogluteal, vastus lateralis, or deltoid. Subcutaneous: abdomen, avoiding navel (2-inch radius). Rotate sites to prevent lipohypertrophy.
3. Sublingual route
Place tablet under tongue, allow dissolution for 1–2 minutes. Avoid swallowing immediately. Claimed to bypass first-pass metabolism.
Administer 2–3 times per week. Consistent weekly schedule recommended (e.g., Monday/Thursday or Monday/Wednesday/Friday).
4. Timing
Morning dose preferred; may split into twice-daily if higher dose used. Consistency emphasized in bioregulator protocols.
Lyophilized: room temperature, light-protected. Reconstituted: refrigerate 2–8 °C. Bacteriostatic water extends shelf life to ~30 days; sterile water use within 72 hours.
5. Cycle protocol
10–30 day cycles common in Russian tradition. Rest period of 1–3 months between cycles often recommended, though no published evidence for this approach.
IM: 21–23G, 1–1.5 inch. SQ: 25–27G, 5/8 inch. Inject slowly (30–60 seconds for IM).